Posts in Therapeutic Platform
Allarta Life Science
Allarta Life Science

Allarta Life Science is a pre-clinical stage life science company, with a proprietary platform technology to enable curative cell treatments for endocrine disorders such as Lysosomal Storage Disorders/Orphan Diseases, Diabetes and Hemophilia. Allarta is raising a Pre-Series A Bridge financing to support pre-clinical studies (diabetes), determining path to Orphan Drug cell models for small and large animal studies, and R&D investment on pipeline IP and core technologies within the company.

Presenter: Harald Stover, Co-Founder & CEO

Read More
Regenerative Medicine, Infectious Diseases & Vac, Metabolic Diseases, Orphan/Rare Diseases, Therapeutic PlatformDonald Cudmore
Denote
Denote

Denote Therapeutics is developing the allogeneic Double Negative T-cell (DNT) platform for off-the-shelf therapeutics in oncology and certain immune disorders. Denote plans to advance this platform through the development of both unmodified and modified DNT therapies both in-house and in conjunction with partners.

Hear more from this company during the Early Technology Showcase.

Presenter: Robert Verhagen, CEO

Read More
Oncology, Therapeutic PlatformMaura Campbell
Elarex
Elarex

Elarex is commercializing its proprietary PT120 formulation technology, proven to stabilize vaccines and biotherapeutics so that cold chain distribution is no longer required. We recently secured $500k in pre-seed financing (another $400k pending) and were awarded NSERC I2I Grant. Our technical team is assembled and we have three paid pilots ongoing with top tier vaccine manufacturer. Business Development leader added to team. We are seeking $4,000,000 to aggressively pursue mRNA/LNP opportunity,expand leadership and technical team, enhance IP portfolio, and expand number of partners and projects.

Presenter: Robert DeWitte, Co-Founder and CEO

Read More
Infectious Diseases & Vac, Therapeutic PlatformMaura Campbell
Feldan Therapeutics
Feldan Therapeutics

Feldan Therapeutics is a biotechnology company that introduced the Feldan Shuttle, a peptide-based platform that allows safe and efficient delivery of proteins, peptides and small molecules inside cells. This technology has the potential to help treat many diseases by targeting intracellular pathways. Feldan is focused on bringing its two therapeutic applications (topical product for BCC/Gorlin patients and inhaled CRISPR-based therapy for Cystic Fibrosis) to the clinic. The company is looking to raise its Series B round of financing mid-2021 to finance Phase I/II clinical trial of our first-to-human indication (Gorlin syndrome) as well as the pre-clinical phase of our Cystic Fibrosis indication.

Presenter: Francois-Thomas Michaud, Chief Executive Officer

Read More
Oncology, Orphan/Rare Diseases, Therapeutic PlatformDonald Cudmore
Innovakine
Innovakine

Using cutting-edge protein and cell engineering approaches, Innovakine has developed a proprietary platform technology that allows clinicians to send exclusive, customized signals to immune cells and other cell types anywhere in the body, with broad clinical applications in the fields of cancer immunotherapy, infectious disease, autoimmunity, transplantation and regenerative medicine. Innovakine was founded in 2019 by Brad Nelson PhD (Distinguished Scientist, British Columbia Cancer; Professor, UBC) and Martin Boulanger PhD (Professor, University of Victoria) following a successful research collaboration with Zymeworks Inc., a clinical-stage biotechnology company. Innovakine is raising $4M in seed funding to complete pre-clinical POC studies in murine solid tumor models.

Presenter: Brad Nelson, Co-founder and CEO

Read More
Therapeutic Platform, Oncology, Regenerative Medicine, Infectious Diseases & VacMaura Campbell
IntelliStem
IntelliStem

IntelliStem is an early stage biotech company that has created the next generation of cell therapy products to target catastrophic diseases such as cancer and Infectious diseases. Its first product “Super Sentinel CellsTM” is an off-the-shelf product to target cancer that has shown an 80% success rate compared to 20% of incumbents In-vivo, which can target both blood and solid tumors offering scalable and more efficacious solutions, at a fraction of the cost of the current platforms. We hope to use investor funds to advance our assets to market through clinical trials, then out-licensing and co-development.

Presenter: Riam Shammaa, Chief Executive Officer and Co-Founder

Read More
Oncology, Infectious Diseases & Vac, Therapeutic PlatformMaura Campbell
JN Nova Pharma Inc.
JN Nova Pharma Inc.

JN Nova Pharma Inc’s lead therapeutic molecule, JN2019, is a potent corona viral neutralizing agent, acting via an enhanced ACE2 decoy, which inhibits viral entry and is immunologically conjugated to cause viral clearance. By simultaneously replacing the lost ACE2 function, it potentially will counteract the deleterious effects of acute respiratory disease syndrome (ARDS) and reduce pathogenic innate immune activation and inflammation caused by the virus.

Presenter: John Gillard, CEO

Read More
Therapeutic Platform, Infectious Diseases & VacMaura Campbell
Mediphage Bioceuticals
Mediphage Bioceuticals

Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.

Presenter: Alvaro Amorrortu, CEO & President

Read More
Neurodegenerative & CNS D, Regenerative Medicine, Infectious Diseases & Vac, Metabolic Diseases, Therapeutic Platform, Ophthalmology, Orphan/Rare Diseases, HepatologyDonald Cudmore
Mesentech
Mesentech

Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These chemical conjugates liberate the active pharmaceutical only in the targeted tissue thereby eliminating side effects caused by systemic exposure. Mesentech’s lead program is a bone-targeted anabolic that stimulates bone regeneration. It is indicated for severe pediatric osteoporosis caused by brittle bone disease, Duchenne muscular dystrophy and as a consequence of steroid treatment.

Presenter: Jonathan Polak, CEO

Read More
Regenerative Medicine, Therapeutic Platform, Metabolic DiseasesDonald Cudmore
Mobio Interactive
Mobio Interactive

Mobio Interactive is a revenue-generating digital therapeutics company that develops and commercializes clinically validated and objectively quantified software to prevent, measure and treat mental illness. Mobio’s recent progress includes completion of a clinical trial with cancer patients, demonstrating equivalent effect sizes on psychological wellbeing from the DTx Am Mindfulness as compared to group psychotherapy. Mobio is raising Series A capital to support clinical trials, IP protection, payor & partner negotiations, regulatory approval, and DTx sales.

Presenter: Bechara Saab, CEO

Read More
Therapeutic Platform, Artificial Intelligence &, Digital Health, OncologyDonald Cudmore
Morphocell Technologies
Morphocell Technologies

Morphocell Technologies is a regenerative medicine company developing an extensive therapeutic platform based on its allogeneic stem cell-derived engineered liver tissues (ELT). Its mission is to transform the treatment of liver disease by the means of cell therapy. With $2.1M in pre-seed funding, we significantly de-risked the technology, collected compelling efficacy/safety data and addressed key scalability hurdles in manufacturing. We are seeking $4.5M to confirm the efficacy and safety of the ELT in large animals. Achieving this key value inflection point would trigger a larger series A investment from already engaged parties, thus enabling pre-clinical development up to CTA/IND application.

Presenter: Massimiliano Paganelli, Co-founder and CEO

Read More
Regenerative Medicine, Therapeutic Platform, HepatologyMaura Campbell
Orion Biotechnology Canada
Orion Biotechnology Canada

Orion Biotechnology is a clinical stage biotechnology company developing GPCR-targeted therapeutics for the treatment of cancer and other serious diseases. This novel scientific approach is enabled by Orion’s proprietary high-throughput drug discovery platform. Our disruptive analog-based technologies position OB to become a premier GPCR-focused company to deliver next generation therapeutics not only for Orion’s pipeline, but also in collaboration with other biopharmaceutical companies. We plan to advance our lead candidate into Phase 1b/2a trial in Oncology and complete lead optimization of 2 additional drug candidates.

Presenter: Antaole Klepatskyi, COO

Read More
Oncology, Infectious Diseases & Vac, Therapeutic PlatformDonald Cudmore
Ovensa Inc.
Ovensa Inc.

Ovensa Inc. is a preclinical stage biotech company advancing its siRNA lead candidate silencing galectin-1 (Gal-1) overexpression in the tumor microenvironment to improve therapeutic outcomes of immuno-oncology checkpoint inhibitors as a combination therapy in head & neck cancer. Ovensa currently works with pharmaceutical companies to formulate their drugs into nanoparticles using Ovensa's TRIOZAN™ drug delivery platform. Most of the collaborations are related to siRNA or mRNA therapeutics where Ovensa offers a non-lipidic approach for intranasal, IV or vaccines delivery.

Presenter: Stephane Gagne, President & CEO

Read More
Oncology, Therapeutic PlatformDonald Cudmore
PlantForm Corporation
PlantForm Corporation

PlantForm is a biotechnology company headquartered in Guelph, Ontario, Canada, with a proven technology used to develop and manufacture high value proteins and antibodies as diagnostics, drugs, and vaccines. PlantForm’s patented vivoXPRESS® technology uses genetically modified tobacco plants to manufacture very low-cost products using fully contained vertical growth environments. The company is revenue generating from contracts including production of components for COVID-19 diagnostic kits. The proceeds of the financing will advance company's lead medical countermeasure drug through IND enabling and Phase 1 Clinical Studies to enter the market in 2-3 years, no Phase 2 or 3 Clinical trials being required.

Presenter: Don Stewart, CEO

Read More
Infectious Diseases & Vac, Therapeutic PlatformDonald Cudmore
Ripple Therapeutics
Ripple Therapeutics

Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery. Ripple’s Epidel® platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor drug dose and duration to the specific indication. Ripple’s lead program – IBE-814 IVT – is an intravitreal implant targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). A Phase II trial has been initiated in Australia with the first patient treatment expected early 2021.

Presenter: Wendy Naimark, VP, Research & Development

Read More
Therapeutic Platform, OphthalmologyDonald Cudmore
Specific Biologics
Specific Biologics

Specific Biologics is a discovery stage company developing platform gene editing technologies as therapeutics to treat or cure disease through precision gene editing. Our gene editor Dualase is designed to overcome two problems with current gene editor – random DNA insertions / deletions and low frequency repair. Unlike other technologies, Dualase cuts DNA in two spots and leaves non-compatible DNA ends. These ends create precise deletions to disrupt DNA or increase rates of repair to correct DNA. We are raising $2.7 million CAD to advance our programs in cystic fibrosis and oncology in preclinical animal models and further develop the platform.

Presenter: Brent Stead, CEO

Read More
Orphan/Rare Diseases, Therapeutic Platform, OncologyDonald Cudmore
Synmedix
Synmedix

Synmedix is a newly-founded biotechnology company created to commercialize a novel platform that dramatically enhances the effectiveness of antibiotics to address unmet medical need posed by the global health crisis in antibiotic resistance. Synmedix was founded on McMaster University technology, showing that bicarbonate dramatically improves the efficacy and spectrum of several antibiotics enabling the treatment of multidrug-resistant infections. Synmedix is seeking seed funding for preclinical studies leading to an Investigational New Drug (IND) for its lead product BCX-4, azithromycin plus bicarbonate, for a first-in-class treatment of diabetic foot ulcer infections. Clinical development will leverage the FDA’s accelerated 505(b)(2) pathway.

Presenter: Eric Brown, CEO

Read More
Therapeutic Platform, Infectious Diseases & Vac, CardiovascularMaura Campbell
TCRyption Inc.
TCRyption Inc.

TCRyption Inc., a novel TCR-T cell therapy company, with the goal of expanding the availability of T-cell receptor based cellular therapeutic (TCR-T) options as effective and safe therapies across multiple cancers with a high unmet need. The company’s highly diverse and growing TCR bank utilizes the proprietary TCRypt platform, originally created by Dr. Naoto Hirano at University Health Network’s (UHN) Princess Margaret Cancer Centre. With unparalleled sensitivity in its ability to mine physiologically relevant TCR’s, this platform enables the rapid discovery of an expansive bank of TCRs that can be used to better address patient needs. TCRyption was established with an initial $10 million in seed financing from TIO Bioventures.

Presenter: Michael Tusche, Co-CEO

Read More
Oncology, Therapeutic PlatformMaura Campbell
Treadwell Therapeutics
Treadwell Therapeutics

Treadwell Therapeutics is a clinical stage Biotechnology company, driven by novel science, and focused on the development of First in class, best in class or only in class small molecule candidates for unmet needs in oncology. Co-Founded in July of 2019 by Drs. Tak Mak and Mark Bray, Treadwell’s three clinical stage assets have been in development for over a decade by the Therapeutics group at the Campbell Family Institute at UHN. With operations in New York, Boston, San Francisco, Hong Kong, and a substantial footprint in Toronto, Treadwell has a global view and strong local roots. The company was established with a $25M investment from TIO Bioventures.

Presenter: Michael Tusche, Co-CEO

Read More
Therapeutic Platform, OncologyMaura Campbell